Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared ...